China IND application of"Recombinant anti-human IL-17A/F humanized monoclonal antibody injection"for AS indication is accepted by CDE
- Categories:News
- Author:
- Origin:
- Time of issue:2020-12-22 16:21
- Views:
(Summary description)China IND application of"Recombinant anti-human IL-17A/F humanized monoclonal antibody injection"for AS indication is accepted by CDE
China IND application of"Recombinant anti-human IL-17A/F humanized monoclonal antibody injection"for AS indication is accepted by CDE
(Summary description)China IND application of"Recombinant anti-human IL-17A/F humanized monoclonal antibody injection"for AS indication is accepted by CDE
- Categories:News
- Author:
- Origin:
- Time of issue:2020-12-22 16:21
- Views:
China IND application of “Recombinant anti-human IL-17A / F humanized monoclonal antibody injection” for AS indication is accepted by CDE
Scan the QR code to read on your phone
Add
Zhong Guancun Biopharmaceutical Park, NO.5 Kaituo Road,
Haidian District, Beijing City, China, 10084
A1 Northern Building, 218 Xinghu St. Suzhou Industrial Park, Jiangsu Province, China, 215123
COPYRIGHT @2020 Suzhou xinkanghe Biomedical Technology Co., Ltd 苏ICP备19068714号-1 Power by 300.cn Beijing
Follow us